Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinomaJimin Dai(Air Force Engineering University), Jingyao Dai(Air Force Engineering University)Cancer MedicineOctober 11, 201810.1002/cam4.1826Cited by 50SaveCiteExport RISWatch citationsRelated PapersBlockade of mIL‐6R alleviated lipopolysaccharide‐induced systemic inflammatory response syndrome by suppressing NF‐κB‐mediated Ccl2 expression and inflammasome activation|MedComm|2022|9